LONG MINI FUTURE - NOVO-NORDISK B Share Price

Certificat

MNOBKV

CH1290585483

Market Closed - Swiss Exchange 08:50:00 30/04/2024 pm IST
0.76 ^CHF	+1.33%

3 months	+90.00%
6 months	+171.43%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart NOVO NORDISK A/S

Latest news about NOVO NORDISK A/S

Roughly 1 in 8 US adults have taken GLP-1 drugs like Wegovy, poll shows	10/05	RE
India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says	10/05	RE
Equity Research \| NANEXA: Insights from CMD underscore near- to mid-term opportunities with significant potential	10/05	AQ
Health Care Climbs as Obesity-Drug Optimism Returns - Health Care Roundup	10/05	DJ

More news

Static data

Product type	Certificat Turbo Stop Loss
Buy / Sell	CALL
Underlying	NOVO NORDISK A/S
Issuer	Vontobel
	MNOBKV
ISIN	CH1290585483
Date issued	31/08/2023
Strike	586.1 kr
Maturity	Unlimited
Parity	50 : 1
Emission price	0.23 CHF
Emission volume	N/A
Settlement	règlement en espèces
Currency	CHF

Technical Indicators

Highest since issue	0.85 CHF
Lowest since issue	0.165 CHF
Spread	0.14 CHF
Spread %	16.28%

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

More about the company